nuvasiveNuVasive (Nasdaq:NUVA) shares ticked up today on first-quarter results that came in ahead of the consensus forecast.

The San Diego-based company posted profits of $19.2 million, or 35¢ per share, on sales of $290.8 million for the three months ended March 31, 2022, for a massive bottom-line gain out of the red on sales growth of 7.2%.

Adjusted to exclude one-time items, earnings per share were 54¢, 15¢ ahead of Wall Street, where analysts were looking for sales of $290.8 million.

“I am pleased with our results during the first quarter, which exceeded our expectations,” NuVasive CEO Chris Barry said in a news release. “Despite COVID-19 and macro-economic pressure in the first half of the quarter, our performance reflects the strong health of our business and positions us well for continued growth. Looking ahead to the remainder of the year, we expect our novel technology to drive further differentiation with our surgeon partners. Led by the X360 and C360 systems—including the Simplify Cervical Disc—and the Pulse platform, we are committed to executing on our near- and long-term strategic plan to drive value for our stakeholders.”

NuVasive said it now expects to log adjusted EPS of $2.15 to $2.45, compared with an expectation of $2.05 to $2.35 previously, raising both ends by 10¢. The company increased the low end of its revenue growth projection, raising it from 5% to 6%, with the high end capped at 8%.

NUVA shares were up 3.5% at $58.28 per share in early-morning trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was down 0.5%.